CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 435,916 shares, a decline of 20.1% from the January 15th total of 545,631 shares. Based on an average daily trading volume, of 324,346 shares, the days-to-cover ratio is presently 1.3 days.
Shares of CANF stock opened at $1.16 on Tuesday. CAN-FITE BIOPHA/S has a 1 year low of $1.00 and a 1 year high of $2.25.
A number of equities analysts have weighed in on CANF shares. HC Wainwright set a $8.00 price target on CAN-FITE BIOPHA/S and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research raised CAN-FITE BIOPHA/S from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Monday, February 4th.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2019/02/12/can-fite-biopha-s-canf-short-interest-update.html.
CAN-FITE BIOPHA/S Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Further Reading: Trading Strategy
Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with MarketBeat.com's FREE daily email newsletter.